Do analysts prefer ATHX or CVKD?

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 1,240.21%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ATHX or CVKD more profitable?

Athersys' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Cadrenal Therapeutics N/A -406.41% -273.80%

Do analysts recommend XRTX or ATHX?

Given Athersys' higher possible upside, analysts plainly believe Athersys is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is XRTX or ATHX more profitable?

Athersys' return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -137.85% -108.16% Athersys N/A N/A -223.03%

Do analysts rate RDHL or ATHX?

Given Athersys' higher probable upside, analysts clearly believe Athersys is more favorable than Redhill Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, RDHL or ATHX?

Redhill Biopharma has higher earnings, but lower revenue than Athersys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma N/A N/A -$430K N/A N/A Athersys $146K 0.00 -$72.53M -$2.03 N/A

Is RDHL or ATHX more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Athersys N/A N/A -223.03%

Do analysts rate REVB or ATHX?

Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Revelation Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is REVB or ATHX more profitable?

Athersys' return on equity of 0.00% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Revelation Biosciences N/A -100.19% -82.72% Athersys N/A N/A -223.03%

Which has better valuation & earnings, ATHX or VCNX?

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Vaccinex $388K 6.74 -$20.25M -$48.27 N/A

Is ATHX or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Vaccinex N/A N/A -383.58%

Athersys (ATHX) Competitors

Compare

ATHX vs. CVKD, XRTX, RDHL, REVB, and VCNX

Should you buy Athersys stock or one of its competitors? Athersys's main competitors and comparable companies include Cadrenal Therapeutics (CVKD), XORTX Therapeutics (XRTX), Redhill Biopharma (RDHL), Revelation Biosciences (REVB), and Vaccinex (VCNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athersys compare to Cadrenal Therapeutics?

Athersys (NASDAQ:ATHX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 1,240.21%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.93, meaning that its stock price is 93% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Athersys. MarketBeat recorded 1 mentions for Cadrenal Therapeutics and 0 mentions for Athersys. Cadrenal Therapeutics' average media sentiment score of 0.91 beat Athersys' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
Cadrenal Therapeutics	Positive

Cadrenal Therapeutics has lower revenue, but higher earnings than Athersys. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A

19.4% of Athersys shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Athersys' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Cadrenal Therapeutics	N/A	-406.41%	-273.80%

Summary

Cadrenal Therapeutics beats Athersys on 8 of the 14 factors compared between the two stocks.

How does Athersys compare to XORTX Therapeutics?

XORTX Therapeutics (NASDAQ:XRTX) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, XORTX Therapeutics had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for XORTX Therapeutics and 0 mentions for Athersys. XORTX Therapeutics' average media sentiment score of 0.90 beat Athersys' score of 0.00 indicating that XORTX Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
XORTX Therapeutics	Positive
Athersys	Neutral

XORTX Therapeutics has higher earnings, but lower revenue than Athersys. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.73	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

Given Athersys' higher possible upside, analysts plainly believe Athersys is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Athersys' return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-137.85%	-108.16%
Athersys	N/A	N/A	-223.03%

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 0.0% of Athersys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

XORTX Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

Summary

XORTX Therapeutics beats Athersys on 7 of the 12 factors compared between the two stocks.

How does Athersys compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Redhill Biopharma has a beta of 4.91, suggesting that its stock price is 391% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Athersys	N/A	N/A	-223.03%

Redhill Biopharma has higher earnings, but lower revenue than Athersys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	N/A	N/A	-$430K	N/A	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

Given Athersys' higher probable upside, analysts clearly believe Athersys is more favorable than Redhill Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Redhill Biopharma had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for Redhill Biopharma and 0 mentions for Athersys. Redhill Biopharma's average media sentiment score of 0.61 beat Athersys' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Redhill Biopharma	Positive
Athersys	Neutral

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Redhill Biopharma beats Athersys on 7 of the 10 factors compared between the two stocks.

How does Athersys compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 19.4% of Athersys shares are owned by institutional investors. 4.8% of Revelation Biosciences shares are owned by insiders. Comparatively, 0.0% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Revelation Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market.

In the previous week, Revelation Biosciences had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for Revelation Biosciences and 0 mentions for Athersys. Revelation Biosciences' average media sentiment score of 0.41 beat Athersys' score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Revelation Biosciences	Neutral
Athersys	Neutral

Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Revelation Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Revelation Biosciences has higher earnings, but lower revenue than Athersys. Revelation Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

Athersys' return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
Athersys	N/A	N/A	-223.03%

Summary

Revelation Biosciences beats Athersys on 7 of the 13 factors compared between the two stocks.

How does Athersys compare to Vaccinex?

Athersys (NASDAQ:ATHX) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Athersys' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Vaccinex	Neutral

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Vaccinex	$388K	6.74	-$20.25M	-$48.27	N/A

Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Vaccinex	N/A	N/A	-383.58%

19.4% of Athersys shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Vaccinex beats Athersys on 5 of the 8 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHX vs. The Competition

Export

Metric	Athersys	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$833K	$12.46B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	0.00	653.19	213.39	20.76
Price / Sales	N/A	754.02	580.95	86.44
Price / Cash	N/A	83.43	76.19	51.56
Price / Book	N/A	9.33	10.42	6.01
Net Income	-$72.53M	$2.84B	$3.50B	$380.68M

Athersys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
CVKD Cadrenal Therapeutics	2.9531 of 5 stars	$0.92 -5.3%	$13.00 +1,311.5%	-93.1%	$3.29M	N/A	N/A	5	Gap Up
XRTX XORTX Therapeutics	1.1541 of 5 stars	$1.79 +2.6%	N/A	-67.5%	$3.24M	N/A	N/A	N/A
RDHL Redhill Biopharma	0.8215 of 5 stars	$0.53 +12.2%	N/A	-68.6%	$3.24M	$290K	N/A	210	Gap Up High Trading Volume
REVB Revelation Biosciences	0.6448 of 5 stars	$0.80 -4.0%	N/A	-86.0%	$3.16M	N/A	N/A	9	Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athersys (ATHX) Competitors

ATHX vs. CVKD, XRTX, RDHL, REVB, and VCNX

How does Athersys compare to Cadrenal Therapeutics?

Summary

How does Athersys compare to XORTX Therapeutics?

Summary

How does Athersys compare to Redhill Biopharma?

Summary

How does Athersys compare to Revelation Biosciences?

Summary

How does Athersys compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athersys (ATHX) Competitors

ATHX vs. CVKD, XRTX, RDHL, REVB, and VCNX

How does Athersys compare to Cadrenal Therapeutics?

Do analysts prefer ATHX or CVKD?

Which has more volatility and risk, ATHX or CVKD?

Does the media favor ATHX or CVKD?

Which has higher valuation and earnings, ATHX or CVKD?

Do insiders & institutionals have more ownership in ATHX or CVKD?

Is ATHX or CVKD more profitable?

Summary

How does Athersys compare to XORTX Therapeutics?

Does the media favor XRTX or ATHX?

Which has better earnings and valuation, XRTX or ATHX?

Do analysts recommend XRTX or ATHX?

Is XRTX or ATHX more profitable?

Do insiders & institutionals believe in XRTX or ATHX?

Which has more risk & volatility, XRTX or ATHX?

Summary

How does Athersys compare to Redhill Biopharma?

Which has more volatility and risk, RDHL or ATHX?

Is RDHL or ATHX more profitable?

Which has preferable valuation & earnings, RDHL or ATHX?

Do analysts rate RDHL or ATHX?

Does the media refer more to RDHL or ATHX?

Do institutionals and insiders believe in RDHL or ATHX?

Summary

How does Athersys compare to Revelation Biosciences?

Do insiders and institutionals have more ownership in REVB or ATHX?

Which has more risk & volatility, REVB or ATHX?

Does the media favor REVB or ATHX?

Do analysts rate REVB or ATHX?

Which has higher valuation and earnings, REVB or ATHX?

Is REVB or ATHX more profitable?

Summary

How does Athersys compare to Vaccinex?

Does the media prefer ATHX or VCNX?

Which has better valuation & earnings, ATHX or VCNX?

Which has more risk & volatility, ATHX or VCNX?

Is ATHX or VCNX more profitable?

Do institutionals and insiders hold more shares of ATHX or VCNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools